Kaitlyn D’Onofrio

DocwireNews

Temple University Hospital has become the United States&rsquo; first facility to conduct a non-surgical lung volume reduction in a patient with severe&nbsp;emphysema.&nbsp;The team at Temple Lung Center performed&nbsp;bronchoscopic&nbsp;lung volume reduction using implantation of the&nbsp;Zephyr&reg; Endobronchial Valve (Zephyr&reg; EBV&reg;)&nbsp;for the first time since the FDA granted approval in June.&nbsp;&ldquo;This first procedure post-FDA approval is a turning point in our capabilities to treat severe emphysema using a minimally invasive&nbsp;bronchoscopic&nbsp;option,&rdquo;&nbsp;said Dr. Gerard&nbsp;Criner,&nbsp;Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University (LKSOM) and Director of the Temple Lung Center. &ldquo;We are very excited to be able to clinically offer this therapy to patients with severe emphysema who remain symptomatic despite optimal medical care.&rdquo;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Temple University Hospital has become the first U.S. center to perform bronchoscopic lung volume reduction using implantation of the Zephyr&reg; Endobronchial Valve to treat severe emphysema following U.S. FDA approval. Details here: <a href="https://t.co/5a8FA91kQ2">https://t.co/5a8FA91kQ2</a>
&mdash; Temple Health News (@TempleMedNews) <a href="https://twitter.com/TempleMedNews/status/1031610163810238472?ref_src=twsrc%5Etfw">August 20, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Criner&nbsp;and his team performed the 45-minute procedure on Aug. 10.&nbsp;Use of the&nbsp;Zephyr&reg; EBV&reg;&nbsp;is a less invasive option for patients with emphysema who also suffer from hyperinflation. When air becomes trapped in the lungs, they overinflate, which makes difficult. Once placed, the device deflates the overinflated lobe of the lung and prevents it from inflating further.&nbsp;A team of Temple University Hospital researchers, including&nbsp;Criner, published a study in May highlighting results from the LIBERATE&nbsp;clinical&nbsp;trial. In&nbsp;this&nbsp;trial,&nbsp;which included 190 patients,&nbsp;close to half of&nbsp;Zephyr&reg; EBV&reg;-treated patients experienced improved lung function, and clinical benefits continued 12 months after the procedure.&nbsp;Among the group treated with current emphysema management options, only 17%&nbsp;of patients&nbsp;felt improvement.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A new device intended to help people with severe emphysema breathe easier has received FDA approval. Learn more: <a href="https://t.co/P117C5G4sw">https://t.co/P117C5G4sw</a> <a href="https://t.co/2qzkMfmKW0">pic.twitter.com/2qzkMfmKW0</a>
&mdash; JAMA (@JAMA_current) <a href="https://twitter.com/JAMA_current/status/1026936022809169922?ref_src=twsrc%5Etfw">August 7, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>On Aug. 9, one day before the procedure, the Temple Health Sciences Center Campus held a training for pulmonologists interested in learning how to perform&nbsp;bronchoscopic&nbsp;lung volume reduction&nbsp;with&nbsp;the Zephyr&reg; valve. Pulmonologists from&nbsp;New York&rsquo;s Columbia Presbyterian Hospital;&nbsp;the University of Michigan Medical Center;&nbsp;Banner Health in Phoenix, Arizona;&nbsp;and the University of Chicago Medical Center&nbsp;all participated in the training. Another training is scheduled for Sept. 28, also at Temple.&nbsp;Source: <a href="https://medicine.temple.edu/news/temple-performs-nation%E2%80%99s-first-non-surgical-lung-volume-reduction-patient-severe-emphysema">Temple University</a>&nbsp;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Temple University Performs Nation’s First Bronchoscopic Lung Volume Reduction by Implanting Zephyr Endobronchial Valve

Pulmonology

Temple University Hospital has become the United States’ first facility to conduct a non-surgical lung volume reduction in a patient with severe emphysema.  ...

Temple University Performs Nation’s First Bronchoscopic Lung Volume Reduction by Implanting Zephyr

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe